Utrecht University

Overview

Clinical and Translational Oncology is a PhD program at Utrecht University dedicated to transforming laboratory discoveries into enhanced strategies for cancer prevention, diagnosis, and treatment. This innovative course emphasizes clinically relevant research questions, utilizing advanced experimental models and modern “omics” approaches, often in collaboration with UMC Utrecht and affiliated research institutes.

What You'll Study

The program is structured around your individual PhD project, allowing you to create a comprehensive research plan, conduct experiments, and communicate your findings through scientific reports and presentations.

Core Research Components

• Translational Model Development and Use: Engage with tumor culture protocols and sophisticated preclinical mouse models to explore cancer mechanisms and treatment responses.
• Clinical Question Formulation: Utilize clinical data to identify significant research questions and hypotheses, designing studies that can be validated with experimental evidence.
• Mechanisms of Disease: Delve into topics such as metastasis, tumor recurrence following therapy, and therapy resistance.
• “Omics” and Patient Data: Analyze alterations in tumor DNA, RNA, proteins, and metabolites to characterize tumors and patient-specific biological backgrounds.
• Bioinformatics and Data Analysis: Employ computational methods to interpret extensive multi-omics datasets, supporting translational conclusions.

PhD Outputs

• Regular progress reports as mandated by the PhD framework.
• Scientific communication through presentations and publications.
• Completion of a PhD thesis based on original research.

Entry Requirements

Applicants must possess a Master of Science (MSc) or Bachelor of Science (BSc) degree from an accredited institution, with a minimum of 168 weeks of education.

Career Prospects

Graduates of the Clinical and Translational Oncology program can pursue a variety of career paths, including research positions in academia, industry, and healthcare settings. Opportunities may also exist in regulatory agencies, biotechnology firms, and non-profit organizations focused on cancer research and treatment.